Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YM155 plus Docetaxel in HER2 Negative Metastatic Breast Cancer
NCT01038804Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Dec 2009
- Primary completion
- Jun 2012
- Modality
- Classical Binding Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of sepantronium in breast cancer, sponsored by Astellas Pharma. Started Dec 2009; status: completed.
02
Drugs
sepantronium
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01038804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01038804.